Summit Therapeutics (SMMT) Shares Outstanding (Weighted Average) (2018 - 2026)

Summit Therapeutics has reported Shares Outstanding (Weighted Average) for 9 years, with the latest figure at $775.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 5.06% year-over-year to $775.5 million; the trailing twelve-month figure through Mar 2026 stood at $775.5 million (up 5.06% YoY), and the FY2025 full-year result was $747.7 million, up 4.06% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $775.5 million, up from $741.4 million in the prior quarter.
• The five-year high for Shares Outstanding (Weighted Average) was $775.5 million in Q1 2026, with the low at $140.0 million in Q1 2022.
• Historically, Shares Outstanding (Weighted Average) has averaged $557.7 million across 5 years, with a median of $699.8 million in 2023.
• Annual changes were most pronounced in 2023 — Shares Outstanding (Weighted Average) surged 398.07% — and 2024, when it grew 1.03%.
• Summit Therapeutics' Shares Outstanding (Weighted Average) stood at $193.3 million in 2022, then surged by 220.5% to $619.6 million in 2023, then climbed by 15.96% to $718.5 million in 2024, then rose by 3.18% to $741.4 million in 2025, then advanced by 4.6% to $775.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $775.5 million (Q1 2026), $741.4 million (Q3 2025), and $740.4 million (Q2 2025), per Business Quant data.